What changed for Peripheral Arterial Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Peripheral Arterial Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 268 to 265 (-3)
- Trials on record 2,449 to 2,458 (+9)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Peripheral Arterial Disease yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 113 trials tracked for Peripheral Arterial Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05992896 · results posted 29 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05992896) compared two groups of surgical patients — one receiving liposomal bupivacaine (a longer-acting local anaesthetic delivered in tiny fat particles) and one receiving a placebo (an inactive substitute). Only 3 people in total were enrolled: 1 in the liposomal bupivacaine group and 2 in the placebo group. Of those, 1 person in the placebo group did not complete the trial. The study was measuring how much pain relief medication (specifically opioid-type medicines, expressed as a "morphine equivalent" — a standard way...
-
NCT00707876 · results posted 16 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 119 participants across three groups (called Cohort 1, Cohort 2, and Cohort 3), with 40, 39, and 40 people starting in each group respectively. The trial was comparing two types of MRI scan — one using a contrast agent called ferumoxytol (referred to as VE-MRI) given at three different dose levels, and one done without any contrast agent (noncontrast MRA) — to see how accurately each type of scan could identify problem areas in blood vessels. The main things being measured were how often each scan correctly spotted a...
-
NCT06112054 · results posted 10 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06112054) enrolled 19 participants, all of whom were placed into a single group to undergo the study procedure using a device called the Clotild® Smart Guidewire System (CSGS). This is a specialised guidewire — a thin, flexible wire used during artery procedures — that was being tested for its ability to take electrical measurements inside blocked or narrowed arteries. Seventeen of the 19 participants completed the trial, and two did not complete it (the reasons were not detailed in the reported data). The reported data s...
-
NCT04007055 · results posted 13 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04007055) enrolled 31 people in total — 17 in the experimental group, who were screened and treated for something called "high platelet reactivity" (HPR, meaning their blood platelets were not responding as expected to blood-thinning medication), and 14 in a control group who received standard care based on existing guidelines. By the end of the study, 12 people in each group had completed the trial. The trial was measuring how well blood vessels stayed open after a procedure, as well as tracking serious events such as amp...
-
NCT05208905 · results posted 26 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05208905) enrolled 9 people who received a device called the Esprit BTK — a stent (a small tube placed inside a blood vessel) that releases a drug called everolimus. Eight of the 9 participants completed the study; one did not. The trial was measuring how everolimus moved through participants' blood after the device was implanted — specifically, how much of the drug got into the bloodstream, how quickly it peaked, and how long it took to clear. Blood samples were taken at multiple time points over 60 days, starting from ju...
-
NCT04536038 · results posted 24 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04536038) involved a total of 5,176 people, split into two groups: 3,909 in an "opt-in" group and 1,267 in an "opt-out" group. The trial was looking at two different ways of recruiting people into a follow-on study called GAMEPAD — one where participants had to actively choose to join (opt-in), and one where they were automatically included unless they chose not to be (opt-out). All participants in both groups completed the study period with no drop-outs recorded. The reported data shows that the main thing being measured...
-
NCT01794572 · results posted 12 December 2025
According to the results reported on ClinicalTrials.gov, this trial tested a radiation-based treatment called Total Bone Marrow Irradiation (TBMI) in people with blood cancer. The trial was designed to find the highest radiation dose that could be given without causing unacceptable side effects — this is called a "dose-limiting toxicity" or DLT. Participants were placed into groups receiving increasing total radiation doses: 8 Gy, 10 Gy, 12 Gy, or 14 Gy. A fifth planned group at 16 Gy had no participants enrolled. In total, 13 people took part — 3 at the 8 Gy level, 3 at 10 Gy, 6 at 12 Gy, and...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05103280 · results posted 31 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 10 people who had difficulty walking due to a condition affecting blood flow to the legs (known as claudication). All 10 participants completed the study. The trial was a single-arm study, meaning there was no comparison group — everyone received the same type of intervention. Participants were given a choice between two types of specially designed assistive shoes (either a carbon fibre shoe or a spring-loaded shoe) and wore their chosen pair for three months. The study measured how far participants could walk on a tr...
-
NCT04440839 · results posted 4 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04440839) enrolled 116 people in the telemedicine group and, notably, zero participants in the standard care comparison group. Because no one was enrolled in the standard care group, the trial appears to have run as a single-group study in practice. The trial was measuring how quickly people with wounds received specialist attention, how long it took to have a procedure to improve blood flow to the affected leg, how long wounds took to heal, and whether any amputations occurred — all within the telemedicine group. The rep...
-
NCT03784729 · results posted 20 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 98 people in an acupuncture group and 98 people in a sham (fake) acupuncture group — 196 participants in total. The trial was measuring changes in low back pain-related disability using a questionnaire called the Modified Roland-Morris Disability Questionnaire (RMDQ). This is a 24-question survey where each question asks whether back pain affected a specific daily activity; scores run from 0 to 24, with higher scores meaning greater difficulty. By the end of the study, 86 people in the acupuncture group and 88 in the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05058456 · results posted 8 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 35 people in a single group (meaning everyone received the same treatment — there was no comparison group). The trial was testing a catheter-based procedure called intravascular lithotripsy (IVL), using a device called the Javelin IVL Catheter, for treating blockages in leg arteries. The trial measured two main things: whether the procedure caused any serious health events within 30 days, and whether the procedure successfully opened the blocked artery. Not all participants stayed in the trial to the end — 29 complete...
-
NCT02900924 · results posted 17 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02900924) enrolled 507 people who received a device called the BioMimics 3D Stent, which is placed inside a blood vessel in the leg to help keep it open. The trial was a single-group study — meaning everyone received the same treatment, with no comparison group. The study tracked participants at 30 days, 12 months, and 24 months. By the end of the study, 398 participants were recorded as having completed it, while 109 did not complete all follow-up visits. The reported data shows that for the main safety measure — the num...
-
NCT04120610 · results posted 11 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04120610) enrolled 195 people in total — 52 healthy participants and 143 people with peripheral artery disease (PAD), a condition where the arteries in the legs become narrowed. All 52 healthy participants completed the study, while 83 of the 143 PAD participants completed it (60 did not complete the study, though the reasons were not detailed in the data). The trial was measuring how well a device called FlowMet-R — which measures blood flow in the legs — could identify whether someone had PAD, a severe form called critic...
-
NCT03347383 · results posted 6 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 100 participants, all of whom received a combination treatment involving a drug-coated balloon (DCB) and a stent — two devices used together during a procedure on a narrowed blood vessel in the leg. The trial was designed to track how often participants needed a repeat procedure on the same section of vessel, as well as how well the vessel stayed open over time. Of the 100 people who started the study, 49 were recorded as having completed it, while 51 did not complete it (the reasons were not detailed in the submitted...
-
NCT04881110 · results posted 3 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people in total — 30 in a group that received liraglutide (a medication used in diabetes and weight management) and 30 in a control group. Most participants completed the six-month study: 27 in the liraglutide group and 28 in the control group. The trial was primarily measuring blood oxygen levels in the lower leg — specifically, a reading called transcutaneous oxygen pressure, which is a measure of how much oxygen is reaching the skin and tissues near the ankle. It also tracked a range of secondary measures includ...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05073510 · results posted 27 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 187 participants, with 186 completing the study and 1 not completing it. The trial was testing a device called the BlueDop Vascular Expert (BVE), which is designed to detect peripheral arterial disease (PAD) — a condition where blood flow to the limbs is reduced. The trial compared the BVE device's readings to two existing assessment methods: arterial duplex ultrasound (a standard imaging test) and ABPI (ankle-brachial pressure index, a test that compares blood pressure in the ankle to the arm). Results were recorded...
-
NCT05250102 · results posted 30 October 2024
According to the results reported on ClinicalTrials.gov, this trial involved 23 participants and all 23 completed the study — none dropped out. The trial was looking at how closely readings from a Nellcor pulse oximeter (a device that estimates the level of oxygen in the blood by shining light through the skin) matched readings taken directly from blood samples. The goal was to see how much difference, if any, existed between the two measurement methods. The reported data shows that the main analysis used something called a Bland-Altman analysis, which is a standard way of comparing two diffe...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05837481 · results posted 16 October 2024
According to the results reported on ClinicalTrials.gov, this trial involved 30 people in total — 15 in a guided meditation group and 15 in a control group (who did not receive the meditation). One person in the control group did not complete the study, leaving 14 who finished. The trial was looking at whether it was practical and feasible to introduce guided meditation sessions before and around the time of surgery, and also measured participants' feelings of anxiety and their awareness of their own bodily sensations (called "interoceptive attention"). The reported data shows that all 15 par...
-
NCT04227899 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04227899) enrolled 261 people in total — 173 in the Esprit BTK group and 88 in the balloon angioplasty (PTA) group. The trial was looking at a device-based treatment for blocked arteries below the knee, and it measured two main things: how often serious limb events (such as major amputation or the treated vessel becoming completely blocked) were avoided, and how often serious safety events (major limb problems or death around the time of the procedure) were avoided. The reported data shows the following numbers for the pr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02607033 · results posted 17 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02607033) involved 18 people in total, split into two groups of nine: one group took part in both exercise and weight loss activities, and the other group did exercise only. The trial was measuring changes in leg pain during walking, blood flow to the legs, physical mobility, and muscle and fat composition in the calf muscles, all compared before and after the programme. Seven out of nine participants in the exercise-and-weight-loss group completed the study, while only two out of nine completed it in the exercise-only gro...
-
NCT03363165 · results posted 30 May 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 39 people in total — 18 in the placebo group and 21 in the VM202 group. VM202 is a gene therapy delivered by injection that was being investigated for peripheral artery disease, a condition that can cause pain and difficulty walking due to reduced blood flow in the legs. The trial tracked participants over 12 months and measured things like how far they could walk, blood flow in their calf muscles, and how they felt about their own walking ability and quality of life. The reported data shows that for the main measure...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02374320 · results posted 21 May 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 13 participants, and all 13 completed the study — none dropped out. The trial involved a single group of participants who received an injection called Exparel (a long-acting local anaesthetic delivered in tiny fat particles). The study was measuring two things: changes in the width (diameter) of two blood vessels in the forearm — the radial artery and the ulnar artery — before and after the injection, and self-reported pain levels at the start of the study and again at 30 days. The reported data shows that artery dia...
-
NCT04060797 · results posted 20 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04060797) involved 38 people in total — 19 in a control group and 19 in an "EDN group." All 38 participants completed the study with no drop-outs. The trial was measuring changes in two things: the Ankle Brachial Index (ABI) — a simple ratio comparing blood pressure in the legs to blood pressure in the arms, where a higher number generally indicates better blood flow — and Transcutaneous Oxygen Pressure (TcPO2), a measure of how much oxygen is reaching the skin. Both were tracked at one week, three months, and six months a...
-
NCT02663518 · results posted 10 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02663518) tested a drug called ontorpacept (also known as PF-07901800 or TTI-621) in people with certain blood cancers. The trial ran in four parts, testing different doses of the drug either on its own or combined with other medicines (nivolumab or rituximab). In total, across all parts of the trial, the reported data shows that 273 people took part. The main things the trial was set up to measure were the number of participants who experienced medical events that appeared during treatment (called "treatment-emergent adve...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03446027 · results posted 10 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03446027) enrolled 200 people in total — 102 in the control group and 98 in the device group. Of those, 78 control participants and 80 device participants completed the study. The trial was looking at whether a device made a difference to how far people could walk on a treadmill, compared to a control group, over a period of three months. It also measured quality of life using several questionnaires, and blood flow in a leg artery using ultrasound. The reported data shows that, for the main outcome — total walking distanc...
-
NCT03241459 · results posted 9 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03241459) enrolled 446 people in total — 222 received a device called the SurVeil drug-coated balloon (DCB) and 224 received a device called the IN.PACT Admiral DCB. Both are specialised balloon catheters used in a procedure to open a narrowed artery in the leg. The trial tracked participants over two years, with check-ins at 1, 6, 12, and 24 months. The main things being measured were whether the treated artery remained open without significant re-narrowing over 12 months, and a combined safety measure looking at freedom...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02790931 · results posted 4 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02790931) enrolled 39 people in an intervention group and 39 people in a control group — 78 participants in total. The trial was measuring physical activity levels and walking speed in both groups. However, not everyone completed the study: 15 people in the intervention group and 19 people in the control group finished, meaning a notable number of participants did not complete the trial in each group. The reported data shows three primary measurements were taken. For daily physical activity (counted as steps per week), th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03720704 · results posted 16 February 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 280 people who all received a device called the GORE VIABAHN VBX Balloon Expandable Endoprosthesis — a type of small tube (stent graft) placed inside a blood vessel using a minimally invasive procedure. Of the 280 people who started the trial, 210 completed it, while 70 did not complete it (the reasons for non-completion were not reported in the data provided). The trial had one primary outcome measure, which combined two things: whether the procedure was carried out successfully (meaning the device was delivered and...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03247972 · results posted 16 February 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 30 people with peripheral artery disease (a condition where narrowed arteries reduce blood flow to the limbs). The trial was measuring how platelets — the tiny blood cells involved in clotting — behaved after participants took high-dose statin medication for eight weeks, and then again after a further eight weeks of combining that statin therapy with a medicine called evolocumab. The key question was whether adding evolocumab made any difference to how the platelets clumped together (aggregated) or how strong blood cl...
-
NCT04123093 · results posted 11 December 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04123093) was testing a product called the Noxsano bandage across two phases. Phase 1 involved healthy volunteers, and Phase 2 involved people receiving wound care. In total, 11 healthy volunteers started Phase 1 (10 completed it, and 1 did not), while 2 wound care participants started Phase 2 (neither completed it). The trial was measuring things like any unwanted reactions or side effects from the bandage, as well as wound size (tracked by measuring the length and width of wounds in centimetres). The reported data shows...
See all 113 reported results for Peripheral Arterial Disease
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a very large amount of public research money is currently directed toward Peripheral Arterial Disease, and that investment has been rising year on year. This is an encouraging sign for patients, as sustained and growing funding tends to support ongoing scientific progress, the training of researchers, and the development of new approaches over time. While funding alo...
See the full Peripheral Arterial Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.